Physician profile
Ying Wang
NPI 1336562727
$1,007.64
in general payments reported to CMS, 2019-2025
9 companies · $726 in 2025
The $726 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.09 · 2023: $21.51 · 2024: $216 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.06 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $269.20 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $208.55 | 2024-2025 | Cobenfy |
| Abbvie INC. | $206.54 | 2024-2025 | |
| Alkermes, INC. | $142.60 | 2024-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $63.42 | 2021-2025 | |
| Axsome Therapeutics, INC. | $38.49 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $35.33 | 2025 | Rexulti |
| Janssen Biotech, INC. | $22.00 | 2025 | Tremfya |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.51 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.